Supplementary Figure 2 from The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation

Supplementary Figure 2: Jagged2-depleted MIA PaCa-2 cells exhibited metastatic defects.</p

Supplementary Figure 4 from The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation

Supplementary Figure 4: Gamma-secretase inhibition did not impair MIA PaCa-2 cell migration.</p

Supplementary Figure 1 from The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation

Supplementary Figure 1: Metastatic inhibtion by Jagged2 depletion in BxPC-3 using another shRNA.</p

Supplementary Figure Legends from The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation

Supplementary figure legends.</p

Supplementary Tables 1 and 2 from The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation

Supplementary Tables 1 and 2: Primer sequences used in the study.</p

Supplementary Figure 3 from The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation

Supplementary Figure 3: Jagged1 knockdown had no effect on MIA PaCa-2 cells migration.</p

Supplementary Figure 5 from The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation

Supplementary Figure 5: Jagged1 and Jagged2-Fc are capable of inducing Notch signaling pathway.</p

Supplementary Information from Stabilization of Notch1 by the Hsp90 Chaperone is Crucial for T-Cell Leukemogenesis

Supplementary tables, figures and materials</p

Figure S2 from Metabolic Enzyme DLST Promotes Tumor Aggression and Reveals a Vulnerability to OXPHOS Inhibition in High-Risk Neuroblastoma

Sup. Figure 2</p

Supplementary Figure 1A from Serine Catabolism Regulates Mitochondrial Redox Control during Hypoxia

The correlation of SHMT2 and PHGDH expression in the samples from patients who died from the disease (top panel, pPHGDHvsSHMT1=0.092, pPHGDHvsSHMT2=7.3×10-5) and the correlation found in the samples from patients where the tumor regressed or matured spontaneously (bottom panel, pPHGDHvsSHMT1=0.3, pPHGDHvsSHMT2=0.0084).</p